Targeted radiosensitization in prostate cancer

Current Pharmaceutical Design

Volumn 19, Issue 15, 2013, Pages 2819-2828

  Ghotra, Veerander P S ^a   Geldof, Albert A ^b   Danen, Erik H J ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Prostate cancer; Radiosensitization; Radiotherapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATM PROTEIN; CURCUMIN; EMBELIN; GELATINASE A; GELATINASE B; GENISTEIN; GOSSYPOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PARTHENOLIDE; PROTEIN BCL 2; PROTEIN BCL XL; RAD50 PROTEIN; SMALL INTERFERING RNA; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE; SURVIVIN; VITAMIN D RECEPTOR;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; COMPETITIVE INHIBITION; DIMERIZATION; DNA DAMAGE; DOWN REGULATION; GENETIC ASSOCIATION; HOMOLOGOUS RECOMBINATION; HUMAN; IONIZING RADIATION; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION; UPREGULATION;

DNA DAMAGE; HUMANS; MALE; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION-SENSITIZING AGENTS;

EID: 84876741423     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319150017     Document Type: Article

References (127)

1. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice. Localized prostate cancer. N Engl J Med 2007; 357: 2696-705.
2. Rosser CJ, Gaar M, Porvasnik S. Molecular fingerprinting of radiation resistant tumors: can we apprehend and rehabilitate the suspects? BMC Cancer 2009; 9: 225.
3. Sandfort V, Koch U, Cordes N. Cell adhesion-mediated radioresistance revisited. Int J Radiat Biol 2007; 83: 727-32.
4. Dey S, Spring PM, Arnold S, et al. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. Clin Cancer Res 2003; 9: 1557-65.
5. Nix PA, Greenman J, Cawkwell L, Stafford N. Radioresistant laryngeal cancer: beyond the TNM stage. Clin Otolaryngol Allied Sci 2004; 29: 105-14.
6. Smith BD, Haffty BG. Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat Oncol Investig 1999; 7: 125-44.
7. Aebersold DM, Kollar A, Beer KT, Laissue J, Greiner RH, Djonov V. Involvement of the hepatocyte growth factor/scatter factor receptor c-met and of Bcl-xL in the resistance of oropharyngeal cancer to ionizing radiation. Int J Cancer 2001; 96: 41-54.
8. Uchida D, Kawamata H, Omotehara F, et al. Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int J Cancer 2001; 93: 489-96.
9. Rubin Grandis J, Chakraborty A, Melhem MF, Zeng Q, Tweardy DJ. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997; 15: 409-16.
10. Pigott K, Dische S, Saunders MI. Where exactly does failure occur after radiation in head and neck cancer? Radiother Oncol 1995; 37: 17-9.
11. Shukovsky LJ. Dose, time, volume relationships in squamous cell carcinoma of the supraglottic larynx. Am J Roentgenol Radium Ther Nucl Med 1970; 108: 27-9.
12. Santana P, Pena LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996; 86: 189-99.
13. Liao WC, Haimovitz-Friedman A, Persaud RS, et al. Ataxia telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J Biol Chem 1999; 274: 17908-17.
14. Haimovitz-Friedman A, Kan CC, Ehleiter D, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 1994; 180: 525-35.
15. Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science 1996; 274: 1855-9.
16. Kolesnick RN, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol 1998; 60: 643-65.
17. Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramidemediated programmed cell death by sphingosine-1-phosphate. Nature 1996; 381: 800-3.
18. Olivera A, Kohama T, Edsall L, et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 1999; 147: 545-58.
19. Xia P, Wang L, Gamble JR, Vadas MA. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem 1999; 274: 34499-505.
20. Xia P, Gamble JR, Wang L, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000; 10: 1527-30.
21. Bayerl MG, Bruggeman RD, Conroy EJ, et al. Sphingosine kinase 1 protein and mRNA are overexpressed in non-Hodgkin lymphomas and are attractive targets for novel pharmacological interventions. Leuk Lymphoma 2008; 49: 948-54.
22. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63: 5962-9.
23. Li W, Yu CP, Xia JT, et al. Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients. Clin Cancer Res 2009; 15: 1393-9.
24. Van Brocklyn JR, Jackson CA, Pearl DK, Kotur MS, Snyder PJ, Prior TW. Sphingosine kinase-1 expression correlates with poor survival of patients with glioblastoma multiforme: roles of sphingosine kinase isoforms in growth of glioblastoma cell lines. J Neuropathol Exp Neurol 2005; 64: 695-705.
25. Ruckhaberle E, Rody A, Engels K, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008; 112: 41-52.
26. Nava VE, Cuvillier O, Edsall LC, et al. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 2000; 60: 4468-74.
27. Pchejetski D, Bohler T, Brizuela L, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res; 70: 8651-61.
28. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4.
29. Apakama I, Robinson MC, Walter NM, et al. bcl-2 overexpression combined with p53 protein accumulation correlates with hormonerefractory prostate cancer. Br J Cancer 1996; 74: 1258-62.
30. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996; 156: 1511-6.
31. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-76.
32. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2: 389-98.
33. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-4.
34. McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996; 56: 5594-9.
35. Chaudhary KS, Abel PD, Stamp GW, Lalani E. Differential expression of cell death regulators in response to thapsigargin and adriamycin in Bcl-2 transfected DU145 prostatic cancer cells. J Pathol 2001; 193: 522-9.
36. Scott SL, Higdon R, Beckett L, et al. BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm 2002; 17: 647-56.
37. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004; 23: 1599-607.
38. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nature reviews Molecular cell biology 2002; 3: 401-10.
39. Vucic D. Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Current cancer drug targets 2008; 8: 110-7.
40. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997; 388: 300-4.
41. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clinical Cancer Research 2008; 14: 5000-5.
42. Schimmer AD. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Research 2004; 64: 7183-90.
43. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. The EMBO journal 2003; 22: 2729-40.
44. Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem 2004; 279: 34087-90.
45. Du CY, Fang M, Li YC, Li L, Wang XD. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000; 102: 33-42.
46. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nature genetics 1999; 23: 387-8.
47. Krajewska M, Krajewski S, Banares S, et al. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003; 9: 4914-25.
48. Tamm I, Kornblau SM, Segall H, et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000; 6: 1796-803.
49. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19: 617-23.
50. McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002; 51: 133-40.
51. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 2004; 171: 1855-60.
52. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004; 100: 751-7.
53. Dai Y, Liu M, Tang W, et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin Cancer Res 2008; 14: 7701-10.
54. Dai Y, Desano J, Qu Y, et al. Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. American journal of cancer research 2011; 1: 128-43.
55. Ma BBY, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. Journal of Clinical Oncology 2003; 21: 2760-76.
56. Zhou BBS, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000; 408: 433-9.
57. Stracker TH, Theunissen JWF, Morales M, Petrini JHJ. The Mre11 complex and the metabolism of chromosome breaks: the importance of communicating and holding things together. DNA Repair 2004; 3: 845-54.
58. Moreno-Herrero F, de Jager M, Dekker NH, Kanaar R, Wyman C, Dekker C. Mesoscale conformational changes in the DNA-repair complex Rad50/Mre11/Nbs1 upon binding DNA. Nature 2005; 437: 440-3.
59. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006; 97: 433-47.
60. Shiloh Y. ATM: Sounding the double-strand break alarm. Cold Spring Harb Sym 2000; 65: 527-33.
61. Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 2003; 3: 155-68.
62. Falck J, Coates J, Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005; 434: 605-11.
63. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Research 2004; 64: 2390-6.
64. Fernandez-Capetillo O, Lee A, Nussenzweig M, Nussenzweig A. H2AX: the histone guardian of the genome. DNA Repair (Amst) 2004; 3: 959-67.
65. Stucki M, Jackson SP. gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair (Amst) 2006; 5: 534-43.
66. Choudhury A, Cuddihy A, Bristow RG. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin Radiat Oncol 2006; 16: 51-8.
67. Al Rashid ST, Dellaire G, Cuddihy A, et al. Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res 2005; 65: 10810-21.
68. Angele S, Falconer A, Foster CS, Taniere P, Eeles RA, Hall J. ATM protein overexpression in prostate tumors: possible role in telomere maintenance. American journal of clinical pathology 2004; 121: 231-6.
69. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: Yes or no? Cancer metastasis reviews 2004; 23: 237-57.
70. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003; 63: 1550-4.
71. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res 2004; 64: 8526-33.
72. Fan R, Kumaravel TS, Jalali F, Marrano P, Squire JA, Bristow RG. Defective DNA strand break repair after DNA damage in prostate cancer cells: Implications for genetic instability and prostate cancer progression. Cancer Research 2004; 64: 8526-33.
73. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001; 29: 1534-8.
74. Willems AJ, Dawson SJ, Samaratunga H, et al. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligationdependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. Clinical Cancer Research 2008; 14: 2953-61.
75. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008; 98: 502-7.
76. Gallagher DJ, Gaudet MM, Pal P, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-21.
77. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
78. Wyman C, Ristic D, Kanaar R. Homologous recombinationmediated double-strand break repair. DNA Repair 2004; 3: 827-33.
79. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
80. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADPribosyl) ation reactions in the regulation of nuclear functions. Biochem J 1999; 342 (Pt 2): 249-68.
81. Petermann E, Keil C, Oei SL. Importance of poly(ADP-ribose) polymerases in the regulation of DNA-dependent processes. Cell Mol Life Sci 2005; 62: 731-8.
82. Godon C, Cordelieres FP, Biard D, et al. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res 2008; 36: 4454-64.
83. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15.
84. Chalmers AJ, Lakshman M, Chan N, Bristow RG. Poly(ADPRibose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets. Seminars in Radiation Oncology 2010; 20: 274-81.
85. Fong PC, Boss DS, Yap TA, et al. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. New Engl J Med 2009; 361: 123-34.
86. Stecca C, Gerber GB. Adaptive response to DNA-damaging agents -A review of potential mechanisms. Biochem Pharmacol 1998; 55: 941-51.
87. Prasad AV, Mohan N, Chandrasekar B, Meltz ML. Induction of Transcription of Immediate-Early Genes by Low-Dose Ionizing-Radiation. Radiat Res 1995; 143: 263-72.
88. Weichselbaum RR, Hallahan D, Fuks Z, Kufe D. Radiation Induction of Immediate-Early Genes -Effectors of the Radiation-Stress Response. Int J Radiat Oncol 1994; 30: 229-34.
89. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004; 18: 2195-224.
90. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-63.
91. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-66.
92. Alcamo E, Mizgerd JP, Horwitz BH, et al. Targeted mutation of TNF receptor I rescues the RelA-deficient mouse and reveals a critical role for NF-kappa B in leukocyte recruitment. J Immunol 2001; 167: 1592-600.
93. Chen C, Edelstein LC, Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000; 20: 2687-95.
94. Chilov D, Kukk E, Taira S, et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J Biol Chem 1997; 272: 25176-83.
95. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kappa B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19: 5785-99.
96. Kunsch C, Rosen CA. NF-kappa B subunit-specific regulation of the interleukin-8 promoter. Mol Cell Biol 1993; 13: 6137-46.
97. Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors 2007; 29: 19-35.
98. Felx M, Guyot MC, Isler M, et al. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappaB in human osteosarcoma. Clin Sci (Lond) 2006; 110: 645-54.
99. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80-8.
100. Hong JH, Chiang CS, Campbell IL, Sun JR, Withers HR, Mcbride WH. Induction of Acute-Phase Gene-Expression by Brain Irradiation. Int J Radiat Oncol 1995; 33: 619-26.
101. Orlowski RZ, Baldwin AS. NF-kappa B as a therapeutic target in cancer. Trends Mol Med 2002; 8: 385-9.
102. Baeuerle PA, Baltimore D. NF-kappa B: Ten years after. Cell 1996; 87: 13-20.
103. Xu Y, Kiningham KK, Devalaraja MN, et al. An intronic NFkappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol 1999; 18: 709-22.
104. Kiningham KK, Xu Y, Daosukho C, Popova B, St Clair DK. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. Biochem J 2001; 353: 147-56.
105. Dhar SK, Lynn BC, Daosukho C, St Clair DK. Identification of nucleophosmin as an NF-kappaB co-activator for the induction of the human SOD2 gene. J Biol Chem 2004; 279: 28209-19.
106. Guo GZ, Yan-Sanders Y, Lyn-Cook BD, et al. Manganese superoxide dismutase-mediated gene expression in radiationinduced adaptive responses. Mol Cell Biol 2003; 23: 2362-78.
107. Murley JS, Kataoka Y, Cao D, Li JJ, Oberley LW, Grdina DJ. Delayed radioprotection by NFkappaB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs. Radiat Res 2004; 162: 536-46.
108. Chen GQ, Goeddel DV. TNF-R1 signaling: A beautiful pathway. Science 2002; 296: 1634-5.
109. Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair WH. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 2006; 25: 1554-9.
110. Xu Y, Fang F, St Clair DK, et al. Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 2007; 6: 2048-56.
111. Sun Y, St Clair DK, Fang F, et al. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factorkappaB inhibition and enhanced by the presence of PTEN. Mol Cancer Ther 2007; 6: 2477-86.
112. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Brit J Cancer 2005; 93: 1019-23.
113. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006; 6: 107.
114. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Research 2003; 63: 1550-4.
115. Xu L, Yang DJ, Wang SM, et al. (-)-gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther 2005; 4: 197-205.
116. Kimura K, Bowen C, Spiegel S, Gelmann EP. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiationinduced apoptosis. Cancer Res 1999; 59: 1606-14.
117. Mu ZM, Hachem P, Pollack A. Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 2005; 65: 331-40.
118. An J, Chervin AS, Nie A, Ducoff HS, Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 2007; 26: 652-61.
119. Colletier PJ, Ashoori F, Cowen D, et al. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Int J Radiat Oncol 2000; 48: 1507-12.
120. Mu ZM, Hachem P, Agrawal S, Pollack A. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int J Radiat Oncol 2004; 58: 336-43.
121. Zhang L, Gokhale P, Mewani R, Li BH, Dritschilo A, Soldatenkov V. Prostate cancer radiosensitization by targeting poly(ADP-ribose) polymerase. Mol Ther 2004; 9: S234-S.
122. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411: 366-74.
123. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004; 279: 55117-26.
124. Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 1999; 20: 199-203.
125. Haber JE. DNA recombination: the replication connection. Trends Biochem Sci 1999; 24: 271-5.
126. Lomonosov M, Anand S, Sangrithi M, Davies R, Venkitaraman AR. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Gene Dev 2003; 17: 3017-22.
127. Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH, Margison GP. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res 2001; 29: 1534-8.